Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | TDP2 | O95551 | 1/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.43 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5552329 | 0.84 | KDM4A (0.41) | KMT2AGAARXFP1KDM4ESMN1; SMN2 | |
| SCHEMBL9808651 | 0.84 | TDP2 (0.45) | HSD17B10TDP2PRMT5WDR77KMT2A | |
| SCHEMBL4636495 | 0.84 | BRD9 (0.45) | HSD17B10TDP2PRMT5WDR77KMT2A | |
| SCHEMBL2149381 | 0.83 | KMT2A (0.41) | KMT2AL3MBTL1GAALMNARXFP1 | |
| SCHEMBL29991286 | 0.82 | GAA (0.63) | KMT2AL3MBTL1GAALMNAPOLB | |
| SCHEMBL5655945 | 0.82 | GAA (0.63) | KMT2AL3MBTL1GAALMNAPOLB | |
| SCHEMBL29115305 | 0.82 | HSD17B10 (0.43) | HSD17B10KMT2AL3MBTL1LMNAPOLB | |
| SCHEMBL3268063 | 0.82 | THRB (0.45) | HSD17B10KMT2AL3MBTL1GAAKDM4E | |
| SCHEMBL29103423 | 0.81 | L3MBTL1 (0.46) | KMT2AL3MBTL1GAALMNAPOLB | |
| SCHEMBL27459158 | 0.81 | TDP2 (0.39) | HSD17B10TDP2PRMT5WDR77KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023178452-A1 | ANTIBODY-DRUG CONJUGATES TARGETING FOLATE RECEPTOR ALPHA AND METHODS OF USE | ZYMEWORKS BC INC. (CA) | 2023-09-28 | — | — | WO | disclosed |
| US-11376260-B2 | Serine/threonine kinase inhibitors | GENENTECH, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| US-20210106593-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2021-04-15 | — | — | US | disclosed |
| US-10842799-B2 | Serine/threonine kinase inhibitors | GENENTECH, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| US-20200078371-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2020-03-12 | — | — | US | disclosed |
| US-20190192534-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2019-06-27 | — | — | US | disclosed |
| US-10278975-B2 | Serine/threonine kinase inhibitors | GENENTECH, INC. (US) | 2019-05-07 | — | — | US | disclosed |
| EP-3077401-B1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH INC (US) | 2018-04-18 | — | — | EP | disclosed |
| US-9867833-B2 | Serine/threonine kinase inhibitors | GENENTECH, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-20180000833-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2018-01-04 | — | — | US | disclosed |
| US-8592398-B2 | 2-amino-4-arylthiazole compounds as TRPA1 antagonists | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2013-11-26 | — | — | US | disclosed |
| EP-2655377-A1 | 2-AMINO-4-ARYLTHIAZOLE COMPOUNDS AS TRPA1 ANTAGONISTS | Glenmark Pharmaceuticals S.A. (CH) | 2013-10-30 | — | — | EP | disclosed |
| EP-2537831-A1 | IMIDAZOLE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-12-26 | — | — | EP | disclosed |
| US-20120316170-A1 | Imidazole Derivative | DAIICHI SANKYO COMPANY LIMITED (JP) | 2012-12-13 | — | — | US | disclosed |
| WO-2012085662-A1 | 2-AMINO-4-ARYLTHIAZOLE COMPOUNDS AS TRPA1 ANTAGONISTS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-06-28 | — | — | WO | disclosed |
| US-20120157411-A1 | 2-AMINO-4-ARYLTHIAZOLE COMPOUNDS AS TRPAI ANTAGONISTS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2012-06-21 | — | — | US | disclosed |
| US-6797731-B2 | USE AS SKIN LIGHTENING AGENTS | PFIZER INC. | 2004-09-28 | — | — | US | disclosed |
| US-20030190298-A1 | Resorcinol derivatives | BRADLEY STUART E (GB) | 2003-10-09 | — | — | US | disclosed |
| US-6541473-B2 | Use as skin lightening agents; 4-(1,4-Dioxaspiro(4.5)dec-8-yl)-1,3-benzenediol for example | WARNER LAMBERT COMPANY | 2003-04-01 | — | — | US | disclosed |
| US-20020137961-A1 | Resorcinol derivatives | PFIZER INC. | 2002-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11376260-B2 | Serine/threonine kinase inhibitors | MAP3K1, MAP3K4, MAP4K2 | HSD17B10 3225/4885TDP2 1624/4885PRMT5 994/4885 |
| US-10842799-B2 | Serine/threonine kinase inhibitors | MAP3K1, MAP3K4, MAP4K2 | HSD17B10 3225/4885TDP2 1624/4885PRMT5 994/4885 |
| US-20030190298-A1 | Resorcinol derivatives | LRAT, NQO1, ALDH1A2 | HSD17B10 331/4885TDP2 2736/4885PRMT5 1477/4885 |
| US-20180000833-A1 | SERINE/THREONINE KINASE INHIBITORS | MAP3K1, MAP3K4, MAP4K2 | HSD17B10 3225/4885TDP2 1624/4885PRMT5 994/4885 |
| US-10278975-B2 | Serine/threonine kinase inhibitors | MAP3K1, MAP3K4, MAP4K2 | HSD17B10 3225/4885TDP2 1624/4885PRMT5 994/4885 |
| US-20190192534-A1 | SERINE/THREONINE KINASE INHIBITORS | MAP3K1, MAP3K4, MAP4K2 | HSD17B10 3225/4885TDP2 1624/4885PRMT5 994/4885 |
| US-20210106593-A1 | SERINE/THREONINE KINASE INHIBITORS | MAP3K1, MAP3K4, MAP4K2 | HSD17B10 3225/4885TDP2 1624/4885PRMT5 994/4885 |
| US-20120157411-A1 | 2-AMINO-4-ARYLTHIAZOLE COMPOUNDS AS TRPAI ANTAGONISTS | TRPA1, TRPV1, TRPV2 | HSD17B10 3851/4885TDP2 2320/4885PRMT5 4102/4885 |
| US-20200078371-A1 | SERINE/THREONINE KINASE INHIBITORS | MAP3K1, MAP3K4, MAP4K2 | HSD17B10 3225/4885TDP2 1624/4885PRMT5 994/4885 |
| US-20020137961-A1 | Resorcinol derivatives | LRAT, NQO1, ALDH1A2 | HSD17B10 331/4885TDP2 2736/4885PRMT5 1477/4885 |
| US-20120316170-A1 | Imidazole Derivative | S1PR2, S1PR1, SPHK2 | HSD17B10 636/4885TDP2 1640/4885PRMT5 2362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.